Company / Interest Expense
Taysha Gene Therapies, Inc. Interest Expense History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$3.8M
FY2023
5-year range
$1.4M / $3.8M
FY2020-FY2023
Trend
+166.0%
vs FY2022
Sector context
#36 of 44
Health Care
What the data says
Taysha Gene Therapies, Inc.'s interest expense of $4M is lower than 82% of companies in the Health Care sector (FY2023). Increased from $1M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2023 with a 3-year CAGR of +413.8%.
Increased from $1M to $4M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +413.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 44This company $3.8M Sector average $291.0M
▼
-98.7% below sector average
Key checks
Key Insights
- 3-year CAGR of +413.8%, indicating consistent growth.
- In FY2023, interest expense increased 166.0% year-over-year.
- Ranks #36 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $3.8M | +166.0% |
| FY2022 | $1.4M | +0.0% |
| FY2021 | $1.4M | +5000.0% |
| FY2020 | $28.0K | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026